Boehringer-Ingelheim
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.
Boehringer Ingelheim's Afatinib Effective for Both Asian, Non-Asian Patients With EGFR-Mutated NSCLC
A pooled analysis of clinical trials and real-world data shows that the anti-tumor activity of Boehringer Ingelheim's TKI is unaffected by patients' ethnicity.
Final Analysis of Real-World Study Supports Sequential Gilotrif, Tagrisso for EGFR-Mutated NSCLC
The final GioTag data suggests a survival benefit with the regimen among patients with EGFR-mutant NSCLC harboring acquired T790M resistance mutations.
Real-World Data Reinforces Survival Benefit of Sequential Gilotrif, Tagrisso in EGFR-Mutated NSCLC
Outcomes from the US cohort of the GioTag study confirm the benefit of Tagrisso for NSCLC patients who have become resistant to first-line Gilotrif.Â
Lung Cancer Survival Benefit From Gilotrif, Tagrisso Sequence Therapy Emerges from Real-World Data
An updated analysis from the GioTag study supports the rationale for giving Gilotrif followed by Tagrisso in patients with EGFR Del19-positive lung cancer.